EnglishFrenchGermanItalianSpanish

Interview with Jeff Williams

NeuMoDx™ Molecular was recently at ECCMID displaying our NeuMoDx™ Molecular 288 System. Our system is capable of automated extraction and isolation of nucleic acids from multiple specimen types, as well as the automated amplification and detection of target nucleic acid sequences by fluorescence-based PCR.

Listen to Jeff Williams, Chairman and CEO of NeuMoDx™ Molecular, explain why the NeuMoDx™ system is a game changer for automated PCR in the video below.

Coronavirus Assay Information

NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on providing testing solutions to hospital and commercial reference laboratories, has developed a SARS-CoV-2 Assay for use on the high throughput, fully automated NeuMoDx™ 288 and 96 Molecular Systems. The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the NeuMoDx™ SARS-CoV-2 Assay implemented on the NeuMoDx™ Molecular Systems.

To learn more about SARS-CoV-2 testing, click here.
To order, click here.